EGFR and non-small cell lung carcinoma: This new network meta-analysis evaluated the efficacy and tolerability of all first-line therapies of TKI-based combination regimens (EGFR-TKI combination therapy) versus osimertinib in advanced EGFR-mutated NSCLC, which is currently the mainstream recognized low toxicity, effective preferred protocol, based on the FLAURA study.[18,19] The results showed that osimertinib provided better PFS and lower TEAEs compared to SOC.